Douglas Slain, Pharm.D., BCPS, FCCP

Associate Professor

Department of Clinical Pharmacy
West Virginia University School of Pharmacy
1124 Health Sciences North
P.O. Box 9520
Morgantown, WV 26506-9520

Phone: (304)293.1462
Fax: (304)293.7672
E-Mail: dslain@hsc.wvu.edu
Link to Full CV - PDF

BIOSKETCH

Dr. Slain, Pharm.D is currently an Associate Professor at West Virginia University. He received his Pharmacy degree and his Doctor of Pharmacy (Pharm.D.) degree from Duquesne University in Pittsburgh. He then completed a residency and fellowship in infectious diseases pharmacotherapy at the Medical College of Virginia in Richmond. Additionally, he has the distinction of being a Board Certified Pharmacotherapy Specialist (BCPS).

Dr. Slain is an anti-infective clinical specialist on the WVU Infectious Diseases Consult Service and in the outpatient Infectious Diseases Clinic. In addition, he teaches in several courses in the schools of Pharmacy, Medicine, and Graduate Nursing. He has received multiple teaching awards for his novel teaching approaches in the School of Pharmacy.

Dr. Slain is active at the national level in several infectious diseases and pharmacy associations. Dr. Slain was selected as "Clinician of the Year" by The Society of Infectious Diseases Pharmacists (SIDP). He is WVU’s faculty liaison to two national associations that serve the needs of clinical pharmacy practitioners (The American Society of Health-System Pharmacist (ASHP) and The American College of Clinical Pharmacy (ACCP). He is the program director and principal mentor for the Infectious Diseases Pharmacotherapy Specialized Residency.

Dr. Slain’s research has been published in respected peer-reviewed journals. Dr. Slain speaks frequently at regional and national meetings and conferences. In addition, he serves as a consultant to the Pharmaceutical industry and to other health care institutions.

EDUCATION

Infectious Diseases Residency & Fellowship, Virginia Commonwealth University-
Medical College of Virginia Richmond, Virginia, 1997-1999

Doctor of Pharmacy, Duquesne University, Pittsburgh, Pennsylvania, 1995-1997

Bachelor of Science in Pharmacy, Duquesne University, Pittsburgh, Pennsylvania, 1985-1990

TEACHING INTERESTS AND COURSES TAUGHT

Courses taught:

PHAR 730 Pharmacotherapeutics III, Coordinator and Instructor
PHAR 739 Therapeutic Patient Monitoring, Instructor
PHAR 760 Acute Care Clinical Rotation-Infectious Diseases, Clinical Preceptor
PHAR 735 Pharmaceutical Care Lab-5, Instructor
PCOL 760 Medical Pharmacology – WVU Medical School, Instructor
NURS 391 Advanced Pharmacology for Nurse Practitioner Program, Instructor

PRACTICE INTERESTS

Dr. Slain’s clinical practice sites at WVU include the Infectious Diseases Consult Service and the outpatient Infectious Diseases clinic. He is a member of WVU Hospitals Antibiotic Committee of the Pharmacy and Therapeutics Committee. He is a key member in the institution’s antibiotic stewardship program

RESEARCH AND SCHOLARSHIP INTERESTS

Antifungal therapies
Anti-infective drug interactions
Respiratory tract infections
Antibiotic resistance
Antiretroviral pharmacokinetics
Antimicrobial use outcomes

SELECTED PUBLICATIONS

Research Articles
Slain D, Sarwari AR, Petros KO, McKnight R, Sager R, Mullett CJ, Wilson A, Thomas JG, Moffett K, Palmer HC, Dedhia HV. Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit. Crit Care Res Pract 2011; (2011): Article ID 416426. 
 
Amsden JR, Slain D. Antifungal Dosing in Obesity: A Review of the Literature. Curr Fungal Infect Rep 2011;5:83-91.
 
Bryant AM, Slain D, Cumpston A, Craig M. A post marketing evaluation of posaconazole plasma concentrations in neutropenic patients with hematologic malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011;37;266-9.
 
Gizzi L, Slain D, Hare J, Sager R, Briggs F, Palmer HC. An Assessment of a Safety Enhancement to the Hospital Medication Reconciliation Process for Elderly Patients. Am J Geriatr Pharmacother 2010;8:127-35.

Slain D, Amsden J.R., Khakoo R.A., Fisher M.A., Lalka D., Hobbs G.R. Effect of High-Dose Vitamin C on the Steady-State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers. Pharmacotherapy 2005;25:165-70.

Slain D, Abate M, Hodges BM, Stamatakis MK, Wolak S. Evaluation of an interactive response system to promote active learning and skills development in the doctor of pharmacy curriculum. Am J Pharm Educ 2004;68(5):Article 117.

Stamatakis MK, Schreiber JM, Slain D, Gunel E. Vancomycin administration during dialysis with low-flux polysulfone membranes: Traditional versus a supplemental dosage regimen. Am J Health-Sys Pharm 2003;60:1564-8.

Slain D, Miller K, Khakoo RA, Fisher MA, Wierman T, Jozefczyk K. Infrequent Occurrence of Amphotericin B Lipid Complex (ABLC)-Associated Nephrotoxicity in Various Clinical Settings at a University Hospital. Clinical Therapeutics 2002; 24:1636-42.

Slain D, Casdorph D, McIntire T. Assessment Of An Antiretroviral Adherence Sensitivity Training Exercise In The Doctor Of Pharmacy Curriculum. Am J Pharm Educ 2002: 66: 277-80.

Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg S, Lou Y, Moore KHP, Wooley J, Stein DS. Metabolic disposition and pharmacokinetics of [14C]-Amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered in a single, oral dose to healthy male subjects. J Clin Pharmacol 2001; 41: 386-96.

Slain D, Pakyz A, Israel D, Monroe SG, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000;20:898-907.
Review Articles

Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: A focus on current and future antifungal treatment options. Pharmacotherapy 2007; 27: 1711-21.

Slain D, Rogers RD, Chapman S, Cleary J. Intravenous hydroxypropyl-b-cyclodextrin formulation of itraconazole: Formulary focus. Ann Pharmacother 2001; 35: 720-9.

Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999;19 (3):306-23.
Book Chapters

Slain D. Invasive fungal infections. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 7th Edition. McGraw-Hill, New York, 2007.

Bergman S, Slain D. Dermatophytosis. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 7th Edition. McGraw-Hill, New York, 2007.

Slain D. Infections in immunocompromised patients: A patient-focused approach. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 7th Edition. McGraw-Hill, New York, 2007.

Slain D. Antifungal Agents: Clinical Significance section (chapter 40), In: Williams DA, Lemke TL, Eds. Foye’s Principles of Medicinal Chemistry, 6th Edition. Lippincott Williams & Wilkins, Philadelphia, 2007.

Slain D. Antiviral Agents and Protease Inhibitors: Clinical Significance section (chapter 43), In: Williams DA, Lemke TL, Eds. Foye’s Principles of Medicinal Chemistry, 6th Edition. Lippincott Williams & Wilkins, Philadelphia, 2007.

Slain D. Pneumonia [Chapter 75]. In: Helms RA, Quan DJ, Eds. Textbook of Therapeutics: Drug and Disease Management, 8th edition. Lippincott Williams & Wilkins, Philadelphia, 2006.

Hodges B, Slain D. Ventilator-Associated Pneumonia [Case 30]. In: Helms RA, Quan DJ, Eds. Textbook of Therapeutics: Drug and Disease Management, 8th edition. Lippincott Williams & Wilkins, Philadelphia, 2006.

Slain D. Infections in immunocompromised patients (Chapter 132): A patient-focused approach. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 6th Edition. McGraw-Hill, New York, 2005.

SELECTED PRESENTATIONS

Antimicrobial stewardship programs: How good is the data? Presented at the 46th Midyear Clinical Meeting of the American Society of Health-System Pharmacists, New Orleans, LA. December 5, 2011. 
 
Antibiotic Stewardship: An essential part of an infection control program. Three Rivers Association For Professionals in Infection Control (TRAPIC) Annual Meeting, Pittsburgh, PA October 14, 2011.
 
Anti-influenza Agents: Current and Future. Presented at the 45th Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Anaheim, CA. December 6, 2010. 
 
Clinical Practice Guidelines for the Management of Candidiasis. Presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Boston, MA. September 11, 2010.
 
Preparing for faculty positions: Insights from the Ivory Tower. Presented at the 44th Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV. December 6, 2009. 
 
Oral Vancomycin Formulations: An Infectious Diseases Pharmacist Perspective. Meeting of The Food and Drug Administration (FDA) Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (ACPS-CP).  Silver Spring, MD. August 4, 2009.
 
Infectious Diseases Therapeutics: What you must know about antimicrobial therapy in the era of resistance. Cross Country Education Continuing Education Symposia. Chicago, IL. July 28th-30th, 2009.
 
Healthcare-Associated Infections: Implications for Prudent Empiric Antibiotic Therapy. 43rd  Annual American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Orlando, FL. December 8, 2008.
 
Infectious Diseases Residencies: A Preceptor Development Forum. Annual Meeting of the Society of Infectious Diseases Pharmacists (SIDP). Washington, D.C. October 24, 2008.

An Update on HIV Therapeutics for Pharmacists. Virginia Society of Health-System Pharmacists (VSHP) Annual Meeting, April 14-15, 2007, Wintergreen Resort, VA.

Treatment Of Fungal Pathogens In The Immunocompromised Patient. 16th Annual Conference of the National Home Infusion Association. Savannah, GA. February 26- March 1, 2007

Drugs vs. Bugs: A Concise Review of Key Issues in Anti-Infective Therapeutics. 41st Annual American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Anaheim, CA. December 9, 2006.

Empiric Therapy Decisions for Serious Infections: A Consideration of Appropriate Therapy. Pharmacotherapy Grand Rounds. University of Tennessee, Memphis, TN November 16, 2006

Antimicrobials and Resistance. 2006 OVMC Infectious Diseases Symposium. Ohio Valley Medical Center, Wheeling, WV. October 7, 2006.

Safeguards for Serious Infections: A Consideration of Appropriate Empiric Antibiotic Therapy. Virginia Society of Health-System Pharmacists Meeting, Region IV. Richmond, VA. October 27, 2005.

A Seasoned Look at Newer Antifungals: Truly Advantageous or is Redundazole Here? Annual Meeting of the American College of Clinical Pharmacy. San Francisco, October 23-26, 2005

New Anti-Infectives and the Treatment of Resistant Organisms. 14th Annual Meeting of the National Home Infusion Association. New Orleans, LA. February 13, 2005.

Clinical Management of Fungal Infections. 14th Annual Meeting of the National Home Infusion Association. New Orleans, LA. February 13, 2005.

Linezolid vs.Vancomycin for the Treatment of Nosocomial or Ventilator-Associated Pneumonia. Significant Paper Session. Annual Meeting of the American College of Clinical Pharmacy. Dallas, TX. October 24-27, 2004.

New Antifungal Formulations. 38th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting. New Orleans, LA. December 9, 2003.